Dysregulated signaling of the Ras/Raf/MEK/ERK cascade has been observed in many malignancies, including leukemias [2, 5–7], and these findings have stimulated an interest in developing specific inhibitors of this pathway [8–11]. Here, MAP2K7 is linked to leukemia.